Matrine inhibits the Wnt3a/β-catenin/TCF7L2 signaling pathway in experimental autoimmune encephalomyelitis

Area of Science:

• Neuroscience
• Immunology
• Pharmacology

Background:

• Oligodendrocyte (OL) dysfunction and impaired remyelination contribute to neurological decline in multiple sclerosis (MS) and its animal model, experimental autoimmune encephalomyelitis (EAE).
• Matrine (MAT), a natural compound from Sophora flavescens, exhibits anti-inflammatory and neuroregenerative properties within the central nervous system (CNS).

Purpose of the Study:

• To investigate the mechanism by which Matrine (MAT) influences the Wnt/β-catenin/TCF7L2 pathway, a known inhibitor of myelination, in the context of MOG35-55 peptide-induced EAE.
• To assess MAT's effect on oligodendrocyte maturation and myelin repair in EAE.

Main Methods:

• Mice with MOG35-55 peptide-induced EAE were treated with Matrine (MAT).
• The study analyzed the activation of the Wnt/β-catenin/TCF7L2 pathway components (Wnt3a, β-catenin, GSK3β) and target genes (cyclin D1, Axin2) in the CNS.
• Oligodendrocyte maturation and myelination were evaluated by quantifying specific cell populations (NG2+Olig2+, MBP+Olig2+, CC1+Olig2+).

Main Results:

• MAT treatment significantly reduced Wnt3a and β-catenin activation in the CNS of EAE mice.
• MAT treatment led to GSK3β activation and decreased expression of Wnt target genes cyclin D1 and Axin2.
• MAT administration promoted oligodendrocyte maturation and enhanced myelination, indicated by changes in specific cell markers.

Conclusions:

• Matrine (MAT) treatment effectively modulates the Wnt/β-catenin/TCF7L2 signaling pathway in the EAE model.
• MAT promotes oligodendrocyte maturation and myelin repair, suggesting its therapeutic potential for demyelinating diseases like MS.